Gonadorelin Evidence Guide
Gonadorelin is FDA-approved as a diagnostic agent for assessing hypothalamic-pituitary-gonadal axis function, with extensive clinical use in fertility workup. As a short-acting GnRH pulse used to stimulate LH/FSH secretion, it also has applications in hypogonadotropic hypogonadism treatment and fertility protocols. A well-validated compound with a real regulatory record.
Our Take
Gonadorelin is FDA-approved as a diagnostic agent for assessing hypothalamic-pituitary-gonadal axis function, with extensive clinical use in fertility workup. As a short-acting GnRH pulse used to stimulate LH/FSH secretion, it also has applications in hypogonadotropic hypogonadism treatment and fertility protocols. A well-validated compound with a real regulatory record.
- Best for
- HPA axis diagnostic testing, hypogonadotropic hypogonadism treatment, fertility protocol support, HPG axis research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 100mcg IV or subcutaneous (diagnostic bolus); pulsatile 5-20mcg every 60-120 min via pump (therapeutic)
Benefits and Evidence
- Pituitary Function Assessment: Level A, includes human evidence - The GnRH stimulation test using gonadorelin is a standard diagnostic tool for evaluating pituitary gonadotrope reserve and differentiating hypothalamic from pituitary causes of hypogonadism.
- Fertility Restoration: Level A, includes human evidence - Pulsatile gonadorelin therapy effectively restores ovulation in women with hypothalamic amenorrhea and spermatogenesis in men with hypogonadotropic hypogonadism. Pregnancy rates comparable to gonadotropin therapy.
- LH/FSH Stimulation: Level A, includes human evidence - Robust, reproducible stimulation of LH and FSH release demonstrated across numerous clinical studies. LH response is typically greater than FSH response.
Side Effects and Warnings
- Injection site reactions
- Headache
- Nausea
- Flushing
- Ovarian hyperstimulation syndrome (with pulsatile therapy in women)
- Multiple pregnancy risk
- Ovarian hyperstimulation syndrome monitoring required during pulsatile therapy
- Not for use in patients with pituitary tumors
Research Dosage References
- <strong>Intravenous (diagnostic)</strong> - 100 mcg - Single bolus - GnRH stimulation test: blood drawn at baseline, 30, and 60 minutes for LH/FSH. Normal response: LH rises 3-6 fold.
- <strong>Subcutaneous (pulsatile pump)</strong> - 5-20 mcg per pulse - Every 60-120 minutes - Pulsatile administration via portable pump for fertility restoration. Mimics physiological GnRH secretion pattern.
Mechanism of Action
Gonadorelin activates the GnRH receptor on pituitary gonadotropes: 1. GnRH receptor binding: Binds to the GnRH receptor (GnRHR), a G-protein coupled receptor on anterior pituitary gonadotrope cells. 2. Gonadotropin release: Triggers release of stored LH and FSH through phospholipase C activation, calcium mobilization, and protein kinase C signaling. 3. Pulsatile physiology: In normal physiology, pulsatile GnRH release (every 60-120 minutes) is required to maintain gonadotropin secretion. Continuous exposure leads to receptor downregulation. 4. Downstream effects: LH stimulates testosterone production (Leydig cells) or ovulation; FSH stimulates spermatogenesis or follicular development.
Legal Status
FDA-approved prescription medication. Not a controlled substance. Available as Factrel (diagnostic) and Lutrepulse/Lutrelef (therapeutic).
Primary Sources
- Pulsatile GnRH therapy for hypothalamic amenorrhea. Journal of Clinical Endocrinology & Metabolism, 1993.
- GnRH stimulation test in the assessment of pubertal disorders. Arquivos Brasileiros de Endocrinologia & Metabologia, 2008.